首页 | 本学科首页   官方微博 | 高级检索  
     


Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter,randomized, double-blind,placebo-controlled,parallel-group trial in Japanese and Korean patients
Authors:Fumihiko Sakai MD  PhD  Norihiro Suzuki MD  PhD  Byung-Kun Kim MD  PhD  Yoshihisa Tatsuoka MD  PhD  Noboru Imai MD  PhD  Xiaoping Ning MD  MS  Miki Ishida BS  Kaori Nagano MS  Katsuhiro Iba MS  Hiroyuki Kondo BA  Nobuyuki Koga MS
Affiliation:1. Saitama International Headache Center, Saitama Neuropsychiatric Institute, Saitama, Japan;2. Department of Neurology, Shonan Keiiku Hospital, Kanagawa, Japan;3. Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea;4. Department of Neurology, Tatsuoka Neurology Clinic, Kyoto, Japan;5. Department of Neurology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan;6. Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA;7. Specialty Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA;8. Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan;9. Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan;10. Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan
Abstract:
Keywords:calcitonin gene-related peptide  episodic migraine  fremanezumab  Japanese  Korean
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号